Aquestive Therapeutics (AQST) Net Margin (2017 - 2026)

Aquestive Therapeutics' Net Margin history runs 10 years deep, the most recent figure standing at 55.77% for Q1 2026.

• In Q1 2026, Net Margin rose 20719.0% year-over-year to 55.77%; the TTM figure through Mar 2026 stood at 1034.08% (down 93406.0% YoY), while the FY2025 annual figure was 8932.2%, down 885552.0% from the prior year.
• Net Margin was 55.77% for Q1 2026 at Aquestive Therapeutics, down from 104.14% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 104.14% in Q4 2025 to a low of 262.96% in Q1 2025.
• Historically, Net Margin has averaged 82.61% across 5 years, with a median of 106.43% in 2024.
• The sharpest annual moves came in 2022 and 2024: Net Margin jumped 41458 bps in 2022, then sank 17889 bps in 2024.
• A 5-year view of Net Margin shows it stood at 115.63% in 2022, then jumped by 47 bps to 61.42% in 2023, then sank by 134 bps to 143.72% in 2024, then soared by 172 bps to 104.14% in 2025, then plunged by 154 bps to 55.77% in 2026.
• The last three Net Margin figures came in at 55.77% (Q1 2026), 104.14% (Q4 2025), and 120.61% (Q3 2025), per Business Quant data.